**Author details**

Mark D. Scott1,2,3\*, Duncheng Wang4 , Wendy M. Toyofuku1,2 and Xining Yang1,2,3

1 Centre for Innovation, Canadian Blood Services, University of British Columbia, Vancouver, BC, Canada

2 Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada

3 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

4 MD Anderson Cancer Center, Houston, Texas, USA

\*Address all correspondence to: mdscott@mail.ubc.ca

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**85**

*DOI: http://dx.doi.org/10.5772/intechopen.86598*

[1] Kaufmann SHE. Immunology's coming of age. Frontiers in Immunology. 2019;**10**:684. DOI: 10.3389/fimmu.2019.00684

[2] Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10-producing regulatory CD4(+

[3] Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: What do we really know? Transfusion Medicine Reviews. 2008;**22**:103-116. DOI: 10.1016/j.tmrv.2007.12.001

[4] Imbach P, Lazarus AH, Kuhne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sanguinis. 2010;**98**:385-394. DOI: 10.1111/j.1423-0410.2009.01264.x

[5] Lazarus AH. Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity. Journal of Clinical Immunology. 2010;**30**(Suppl 1):S20-S23.

DOI: 10.1007/s10875-010-9410-9

[6] Anthony RM, Kobayashi T,

gammaglobulin suppresses

DOI: 10.1038/nature10134

Wermeling F, Ravetch JV. Intravenous

inflammation through a novel T(H)2 pathway. Nature. 2011;**475**:110-113.

[7] Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, et al. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during

cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. The Journal of Experimental Medicine. 2002;**195**:603-616. DOI: 10.1084/

**References**

jem.20011629

*Modulating the T Lymphocyte Immune Response via Secretome Produced…*

graft-versus-host disease or the primary immune response to nominal antigen. The Journal of Immunology.

[8] Delmonico FL, Cosimi AB. Monoclonal antibody treatment of human allograft recipients. Surgery, Gynecology & Obstetrics.

[9] Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versushost disease (GVHD) prevention. Immunological Reviews. 1997;**157**: 79-109. DOI: 10.1111/j.1600-065x.1997.

[10] Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: An overview. Expert Opinion on Pharmacotherapy.

2004;**5**:581-594. DOI: 10.1517/

the 2013 update of the EULAR

[11] Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological diseasemodifying antirheumatic drugs: A systematic literature review informing

recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2014;**73**:516-528. DOI: 10.1136/annrheumdis-2013-204575

[12] Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2014;**73**:529-535. DOI: 10.1136/ annrheumdis-2013-204575

[13] Arora A, Mahajan A, Spurden D, Boyd H, Porter D. Long-term drug survival of TNF inhibitor therapy in RA patients: A systematic

eoph.5.3.581.27357

1997;**159**:5821-5833

1988;**166**:89-98

tb00976.x

) T

*DOI: http://dx.doi.org/10.5772/intechopen.86598 Modulating the T Lymphocyte Immune Response via Secretome Produced…*
